Bayer reports solid Q2 revenues, Q2 sales rise 5.8%

30-Jul-10
Bayers’ revenues have mounted by 14.6% to €9.18 bl, largely due to growth in its consumer health and high-tech materials divisions. Net income has dropped to €525 mln, down from €532 mln a year earlier. Q2 net earnings fell by 1.3% owing to lawsuits and writing down a cancer drug. Bayer has taken special charges of €255 mnl in the quarter, of which €123 mln related to litigation and €132 mln from a partial write-down on cancer drug Zevalin.
  More News  Post Your Comment

Previous News

Next News

{{comment.Name}} made a post.
{{comment.DateTimeStampDisplay}}

{{comment.Comments}}

COMMENTS

0

There are no comments to display. Be the first one to comment!

*

Name Required.

*

Email Id Required.

Email Id Not Valid.

*

Mobile Required.

Email ID and Mobile Number are kept private and will not be shown publicly.
*

Message Required.

Click to Change image  Refresh Captcha